Primary systemic therapy (PST) is considered the standard treatment for locally advanced breast cancer, and its use has substantially increased in recent years ([@bib2]). PST facilitates breast-conserving surgery, initiates early systemic treatment for clinically undetectable micrometastases before surgery ([@bib9]) and allows an evaluation of chemo-sensitivity of tumour against the given chemotherapeutic regimen ([@bib31]). Moreover, the degree of response to PST is considered an indicator of patient outcome, and the patients achieving pathological complete response (pCR) after PST have excellent disease-free and overall survival ([@bib9]). However, the clinical response to PST does not well correlate with the pathological response, and a precise evaluation of chemo-sensitivity to certain chemotherapeutic regimens can only be obtained by microscopic examination of residual tumour on surgical resection specimens after PST. Many studies have therefore been conducted to identify predictive factors for pCR after PST.

It has been shown that the immune system can eliminate tumour cells and control tumour growth by immunosurveillance ([@bib44]) and that the presence of tumour-infiltrating lymphocytes (TILs) is associated with favourable long-term outcome in breast cancer ([@bib1]; [@bib12]; [@bib42]). Moreover, a high level of TILs has been suggested to be a predictive factor for pCR in response to PST in breast cancer ([@bib19]; [@bib13]; [@bib46]; [@bib35]; [@bib24]). However, the subset of lymphocytes that is crucial in this respect has not been determined. CD8+ cytotoxic T lymphocytes (CTLs) have been shown to be associated with favourable response to anthracycline-based PST in breast cancer but have not been proved as an independent predictor of pCR ([@bib23]; [@bib46]).

In contrast to the ascribed protective role of tumour immunity, it has been demonstrated that the immune system, and CD8+ CTLs in particular, can induce tumours to undergo epithelial--mesenchymal transition (EMT) and to acquire breast cancer stem cell (BCSC) properties and thus to have more aggressive behaviour ([@bib38]). BCSCs, represented by CD44+/CD24− and aldehyde dehydrogenase 1 (ALDH1) expression, have been suggested to have an important role in chemo-resistance ([@bib25]; [@bib45]). EMT, which is regarded as an important mechanism of invasion by cancer cells and metastatic progression, was also reported to be associated with chemo-resistance ([@bib10]; [@bib43]). Moreover, EMT is closely related to the BCSC phenotype ([@bib29]). Thus, the possible association of TILs with BCSC and EMT seems to conflict with their effects on the chemo-response. However, the relationship of TILs to BCSC and EMT was not confirmed in human breast cancer samples, and it has not been shown that this relationship affects the significance of TILs as a predictive factor for pCR in breast cancer.

Among breast cancer subtypes, triple-negative or basal-like breast cancers are known to be more sensitive to anthracycline-based chemotherapy than luminal breast cancers ([@bib6]; [@bib3]). However, triple-negative breast cancer (TNBC) is characterised by conspicuous lymphocytic infiltration ([@bib39]) and, as we showed previously, is strongly associated with the BCSC phenotype and EMT ([@bib37]). Therefore, the predictive role of TILs in response to PST needs to be determined in the individual breast cancer subtypes, to avoid bias caused by their close relationship.

This study was designed to assess the association of TIL subsets with pCR in breast cancer patients who received antracycline- or antracycline/taxane-based chemotherapy as a function of breast cancer subtype, BCSC phenotype and EMT. For this purpose, we evaluated TIL subsets (CD4+, CD8+, and FOXP3+), BCSC phenotypes (CD44+/CD24−, and ALDH1), and the expression of EMT markers (vimentin, smooth muscle actin, osteonectin, E-cadherin, and N-cadherin) in pre-chemotherapeutic biopsy specimens and correlated them with pCR after PST in the total group of breast cancer patients and in subgroups according to breast cancer subtype, BCSC phenotype and EMT. We also examined the correlation of TILs with BCSC and EMT in total breast cancer and in the TNBCs.

Materials and methods
=====================

Patients and treatment
----------------------

This retrospective study comprised 153 patients with clinical stage II (*n*=78) or III (*n*=75) breast cancer who underwent breast-conserving surgery or mastectomy after PST in Seoul National University Bundang Hospital from October 2004 to December 2010. All patient samples were obtained before PST by core needle biopsy and diagnosed as invasive breast carcinoma. Of the 153 patients, 66 (43.5%) were treated with the AC regimen consisting of 60 mg m^−2^ doxorubicin i.v. on day 1 and 600 mg m^−2^ cyclophophamide i.v. on day 1 every 3 weeks for 4--6 cycles, and 40 (26%) received sequential ACT comprising 4 cycles of AC followed by 4 cycles of 75 mg m^−2^ docetaxel, and the remaining 47 (30.5%) received the AD regimen consisting of 50 mg m^−2^ doxorubicin i.v. on day 1 and 75 mg m^−2^ docetaxel i.v. on day 1 every 3 weeks for 3--6 cycles. The patients underwent breast surgery about 3--4 weeks after the last chemotherapy cycle.

A pair of formalin-fixed and paraffin-embedded tumour samples, consisting of a pre-chemotherapy biopsy and post-chemotherapy resection specimen, was collected for each patient. Medical records, pathology reports, H&E-stained sections, and immunohistochemical slides for basic biomarkers were reviewed to acquire clinicopathological information, including age, sex, initial clinical T and N stage (by seventh UICC/AJCC), pathological T and N stage after PST, histological subtype (by WHO classification), histological grade (by Bloom and Richardson grading system), presence of carcinoma *in situ*, venous invasion, lymphatic invasion, tumour border, estrogen receptor (ER), progesterone receptor (PR), HER2 status, Ki-67 proliferation index, and p53 overexpression.

pCR was defined as the complete disappearance of all invasive tumour cells from breast tissue and regional lymph nodes regardless of the presence of residual ductal carcinoma *in situ* in the breast. This study was approved by an Institutional Review Board of Seoul National University Bundang Hospital (Protocol No. B-1206/160-301), and informed consent was waived.

Immunohistochemical staining
----------------------------

All immunohistochemical staining except double staining for CD44/CD24 was performed using an automatic immunostainer (BenchMark XT, Ventana Medical Systems, Tucson, AZ, USA) on pre-chemotherapy biopsy specimens. In brief, 4-*μ*m sections were transferred to glass slides coated with poly-L-lysine and dried overnight at 65 °C. They were then subjected to heat-induced antigen retrieval. Staining was optimised using positive and negative controls and primary antibodies directed against TIL markers (CD8, CD4, and FOXP3), BCSC markers (CD44, CD24, ALDH1), and EMT markers (vimentin, smooth muscle actin, osteonectin, N-cadherin, and E-cadherin; [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). The sections were visualised with an UltraView Univeral DAB kit (Ventana Medical Systems).

Double immunostaining to detect CD44+/CD24− cells was performed with EnVision G\|2 Doublestain System Rabbit/Mouse (diaminobenzidene (DAB)+/Permanent Red) (DAKO, Carpinteria, CA, USA) according to the manufacturer\'s instructions. CD44 was detected with DAB and CD24 with Permanent Red.

Quantification of tumour-infiltrating lymphocytes and scoring of markers
------------------------------------------------------------------------

To evaluate the extent of TIL infiltration, we initially scanned all tumour biopsy cores in the immunohistochemically stained slides using × 4 or × 10 objective lens (OLYMPUS BX51, Olympus Optical Co., Ltd, Tokyo, Japan). If the TILs were homogeneously distributed, three high-power fields ( × 40 objective) were selected at random for counting of TILs. In contrast, if its infiltration was heterogeneous, the areas with the highest and lowest infiltration were excluded, and five high-power fields were randomly selected in the rest. We photographed (OLYMPUS DP70 Digital Microscope Camera, Olympus Optical Co., Ltd) the selected representative high-power fields of each case and imported them into UTHSCSA Image Tool software (Version 3.0, Department of Dental Diagnostic Science at The University of Texas Health Science Center, San Antonio, TX, USA). Intratumoural lymphocytes were defined as lymphocytes within tumour cell nests and in direct contact with tumour cells, using the method of [@bib13], and intratumoural CD4+, CD8+, and FOXP3+ lymphocytes were quantified using the cell-counter function. Mean numbers of intratumoural CD4+, CD8+, and FOXP3+ TILs per field, and the ratios of CD8+/CD4+, CD4+/FOXP3+, and CD8+/FOXP3+ TIL were calculated. The median values of the TILs were used as cutoff values, and infiltration of the TILs was categorised as low or high.

The expression of BCSC and EMT markers was scored as the percentage of positive tumour cells in 10% increments. Details of the antibodies and the cutoff values used in the study are given in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

Breast cancer subtypes
----------------------

Breast cancer subtypes were categorised according to the St. Gallen Expert Consensus ([@bib18]) as follows: luminal A type (ER+ and/or PR+, HER2-, Ki-67\<14%), luminal B (ER+ and/or PR+, HER2-, Ki-67⩾14%), luminal B/HER2+ (ER+ and/or PR+, HER2+), HER2+ (ER−, PR−, HER2+) and triple negative (ER−, PR−, HER2−). For ER and PR, cases with ⩾1% positive staining were considered positive. For HER2, 3+ by immunohistochemistry or the presence of gene amplification by fluorescence *in situ* hybridisation was considered HER2 positive.

Statistical analysis
--------------------

All statistical analyses were conducted using Statistical Package for the Social Sciences software (version 17.0, SPSS Inc, Chicago, IL, USA). Non-continuous data were compared by the Chi-square test or the Fisher\'s exact (two-sided) test, and continuous data were analysed by independent-samples *t*-test or the Mann--Whitney *U* test. Spearman\'s rank correlation test was used to assess the correlation between markers. To detect independent predictive factors for pCR, univariate and multivariate binary logistic regression analyses were performed. Backward stepwise model selection was used to build the multivariate logistic regression model, and any possibility of multicollinearity was excluded from the final model. Odds ratios (OR) and their 95% confidence intervals (CI) were estimated for each factor. Statistical significance was set at *P*\<0.05 for each analysis.

Results
=======

Patient characteristics
-----------------------

The clinicopathological characteristics of the patients included in this study are summarised in [Table 1](#tbl1){ref-type="table"}. Of the 153 patients, 20 (13.1%) achieved pCR in the primary breast tissue and affected lymph nodes after PST. There was no statistical difference in pCR rate according to PST regimen, although it tended to be high in the subgroup receiving the ACT regimen. As expected, high histological grade (*P*\<0.001), ER negativity (*P*\<0.001), and high Ki-67 index (*P*\<0.001) were correlated with a higher pCR rate after PST. Of the molecular subtypes, TNBC had the highest pCR rate, significantly higher than in the luminal A and luminal B subtypes (triple-negative *vs* luminal A, *P*\<0.001; triple-negative *vs* luminal B, *P*=0.002).

TIL subsets and their association with the clinicopathological characteristics of tumours
-----------------------------------------------------------------------------------------

We measured intratumoural infiltrates of CD4+, CD8+, and FOXP3+ T lymphocytes in each tumour. Infiltration was quite variable; some cases had prominent infiltrates, others had no infiltration ([Figure 1](#fig1){ref-type="fig"}). The relationships between infiltration of TIL subsets (low *vs* high) and various clinicopathological parameters of the tumours are shown in [Table 2](#tbl2){ref-type="table"}. High levels of infiltration of CD4+, CD8+, and FOXP3+ T lymphocytes were strongly associated with high histological grade (*P*\<0.001, *P*=0.003, *P*=0.002, respectively), ER negativity (*P*=0.006, *P*\<0.001, *P*=0.001, respectively), triple-negative subtype (*P*\<0.001, *P*\<0.001, *P*=0.002, respectively), and high Ki-67 proliferation index (*P*=0.003, *P*=0.043, *P*\<0.001, respectively). Although high level of infiltration of CD4+ T lymphocytes was related to low clinical stage (*P*=0.029), the infiltration of CD8+ and FOXP3+ T lymphocytes showed no relationships with clinical stage (*P*=0.375, *P*=0.228, respectively).

Correlation of TIL subsets with BCSC and EMT
--------------------------------------------

To determine the relationship between TIL subsets and BCSC or EMT in the breast cancers, we analysed the correlation between levels of the TIL subsets and the expression of BCSC and EMT markers. The infiltration of CD4+, CD8+, and FOXP3+ T lymphocytes was highly correlated with each other (*P*\<0.001) and they were closely correlated with the BCSC phenotype and EMT ([Table 3](#tbl3){ref-type="table"}). A high level of CD4+ TILs were positively correlated with the presence of CD44+/CD24− (*P*=0.016) and ALDH1+ (*P*=0.017) tumour cells, as well as the expression of vimentin (*P*\<0.001), smooth muscle actin (*P=*0.009) and osteonectin (*P*=0.002). Similarly, strong infiltration of CD8+ CTLs inter-correlated with the presence of CD44+/CD24− (*P*\<0.001) and ALDH1+ (*P*=0.005) tumour cells and the expression of vimentin (*P*=0.007) and osteonectin (*P*=0.038) ([Figure 2](#fig2){ref-type="fig"}). A high level of FOXP3+ TILs were also positively correlated with ALDH1 (*P*=0.032) and vimentin (*P*\<0.001) expression.

As infiltration of CD4+, CD8+, and FOXP3+ T lymphocytes and expression of BCSC and EMT markers occurred mostly in TNBC ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}), we further analysed the correlation of the TIL subsets with BCSC and EMT within the TNBC. Even within the TNBC, strong infiltration of CD4+ and CD8+ T cells was positively correlated with the presence of CD44+/CD24− tumour cells (*P*=0.014, *P*=0.008, respectively). In addition, strong infiltration of CD4+ T cells was positively correlated with vimentin expression (*P*=0.008; [Table 3](#tbl3){ref-type="table"}).

TIL subsets as predictive factors for pathological complete response
--------------------------------------------------------------------

To assess the relationship between TIL subsets and pCR, we compared the numbers of intratumoural CD4+, CD8+ and FOXP3+ T cells in pCR and non-pCR cases. The patients who achieved pCR had significantly higher number of CD4+, CD8+, and FOXP3+ T-cell infiltrates than the non-pCR patients (*P*=0.003, *P*\<0.001, *P=*0.001, respectively, Mann--Whitney *U* test; [Figure 3](#fig3){ref-type="fig"}). We also analysed the ratios of CD8+/CD4+, CD4+/FOXP3+, and CD8+/FOXP3+ in the pCR and non-pCR groups. The pCR group showed significantly higher CD8+/CD4+ ratio (*P*=0.018, Mann--Whitney *U* test), but not those of CD4+/FOXP3+ (*P*=0.277) and CD8+/FOXP3+ (*P*=0.297), than the non-PCR group ([Figure 3](#fig3){ref-type="fig"}).

As a next step, the levels of CD4+, CD8+, and FOXP3+ TILs (low *vs* high) together with various clinicopathological parameters, and BCSC and EMT markers, were subjected to univariate and multivariate logistic regression analyses to identify independent predictive factors for pCR. In univariate analysis, strong infiltration of CD4+, CD8+, and FOXP3+ T cells, expression of vimentin and osteonectin, and classic predictive factors, including high histological grade and high Ki-67 proliferation index, ER negativity, and TN subtype, were found to be predictive factors for pCR ([Table 4](#tbl4){ref-type="table"}). However, in multivariate analysis, only high Ki-67 index (*P*=0.003; OR, 9.786; 95% CI, 2.121--45.149) and CD8+ TILs (*P*=0.003; OR, 9.786; 95% CI, 2.121--45.149) were independent predictive factors for pCR ([Table 4](#tbl4){ref-type="table"}).

Subgroup analyses according to breast cancer subtype, BCSC phenotype, EMT, and chemotherapeutic regimen
-------------------------------------------------------------------------------------------------------

To confirm the association of CD8+ TILs with pCR irrespective of tumour subtype, we performed subgroup analyses in TNBC and non-TNBC ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). In TNBC, high levels of CD4+, CD8+, and FOXP3+ TILs were associated with pCR (*P*=0.037, *P*=0.038, *P*=0.037, respectively). Other factors, including high Ki-67 proliferation index, and BCSC and EMT markers were not associated with pCR. In non-TNBC, positive HER2 status (*P*\<0.001), high Ki-67 proliferation index (*P*=0.001), and a high level of CD8+ CTLs (*P*=0.033) were associated with pCR.

As the CD44+/CD24− BCSC phenotype was highly correlated with strong infiltration of CD4+ and CD8+ T lymphocytes among total cancers and TNBC, we also performed subgroup analysis according to the CD44+/CD24− phenotype ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}). In tumours with the CD44+/CD24− phenotype, high levels of CD4+, CD8+, and FOXP3+ T lymphocytes (*P*=0.003, *P*=0.002 and *P*=0.020, respectively) and expression of vimentin (*P*\<0.001) were associated with pCR in addition to the other classical predictive factors. However, in tumours without the CD44+/CD24− phenotype, only osteonectin expression (*P*=0.040) was associated with pCR. CD8+ TILs tended to be high in the pCR group (*P*=0.090).

Among the EMT markers examined, vimentin expression was strongly correlated with infiltration of CD4+, CD8+, and FOXP3+ TILs in total and in the TNBCs. Of the TIL subsets, only CD8+ TILs (*P*=0.007) were significantly associated with pCR in tumours expressing vimentin. In tumours not expressing vimentin, the level of CD8+ CTLs tended to be high in the pCR group (*P*=0.137; [Supplementary Table S5](#sup1){ref-type="supplementary-material"}).

Finally, in the subgroup analyses according to PST regimen, high levels of CD4+, CD8+, and FOXP3+ TILs (*P*=0.037, *P*=0.037, *P*=0.037, respectively) were associated with pCR in patients treated with the ACT regimen. In the subgroups treated with the AC and AD regimens, there was no significant association between TILs and pCR. However, CD8+ TILs tended to be high in the pCR group (*P*=0.076, AC regimen; *P*=0.158, AD regimen; [Supplementary Table S6](#sup1){ref-type="supplementary-material"}).

Discussion
==========

Some chemotherapeutic agents, in particular anthracyclines, are supposed to induce specific immune responses that result in immunogenic cancer cell death or immunostimulatory side effects ([@bib47]). Therefore, such chemotherapy may act as an adjuvant for antitumour immunity ([@bib32]). Actually, it has been reported that anthracycline-based chemotherapy promotes tumour infiltration by activated, IFN-*γ*-producing CD8+ T cells ([@bib30]), and anthracycline-based chemotherapy was found to be more efficient when it was administrated to immunocompetent mice than to immunodeficient mice transplanted with similar tumours ([@bib8]). Taxanes also exert immunomodulatory effects on immune cells, some of which may lead to activation of innate and specific immune effectors ([@bib7]; [@bib21]). In particular, paclitaxel simulates macrophages, which show direct cytotoxicity against tumour cells or indirect cytotoxicity by the secretion of cytokines to activate other immune cells to start anti-tumour immune response ([@bib21]). Thus, a higher host immune response against a tumour before treatment may enhance the effect of anthracycline- or antracycline/taxane-based chemotherapy in eliminating cancer cells via further activation of the immune system, which has already been sensitised to tumour antigen.

CD8+ CTLs are crucial components of tumour-specific cellular adaptive immunity, and studies have demonstrated that they are associated with patient survival in various cancers, including colorectal ([@bib16]; [@bib36]) and ovarian cancers ([@bib41]). Recently, it was also reported that a high level of infiltration of CD8+ lymphocytes is an independent prognostic factor for favourable clinical outcome in breast cancer ([@bib11]; [@bib28]; [@bib27]). However, it has not been clear whether CD8+ CTLs are the key component of TILs associated with chemo-response. In this study, we showed that CD8+ TIL infiltration was an independent predictive factor for pCR in breast cancer patients treated with antracycline- or antracycline/taxane-based PST. Furthermore, in subgroup analysis, we found that the CD8+ TIL level was closely correlated with pCR irrespective of breast cancer subtype, CD44+/CD24− BCSC phenotype, EMT, and chemotherapeutic regimen. [@bib46] reported that anthracycline-based adjuvant chemotherapy was beneficial in breast cancer patients with a high level of CD8+ TILs but not for those with a low level of CD8+ TILs. [@bib30] found that the therapeutic efficacy of doxorubicin treatment was dependent on CD8+ CTLs and IFN-*γ* production in an experimental model of breast carcinoma in mice. Moreover, the levels of expression of CD8*α*, CD8*β*, and IFN-*γ* in human breast cancer samples before anthracycline chemotherapy were correlated with clinical response ([@bib30]). Collectively, these results suggest that CD8+ CTLs are the primary component of TILs associated with response to anthracycline-based chemotherapy.

FOXP3+ Treg cells are known to disrupt anti-tumour immunity by suppressing the effector functions of various immune cells and have been implicated in escape of cancer cells from immunosurveillance ([@bib14]). Therefore, we expected that tumours with little infiltration of FOXP3+ Treg cells would be more likely to achieve pCR. However, contrary to this expectation, high-level infiltration of FOXP3+ T lymphocytes was associated with pCR, in accordance with previous studies ([@bib34]; [@bib24]). It has been reported that some chemotherapeutic agents, particularly cyclophosphamide, can inhibit tumour-protective Treg cells. Thus, it could be postulated that suppression of Treg inhibitory function by chemotherapy might be more profound in tumours with high levels of infiltration of FOXP3+ Treg cells, and this in turn would facilitate tumour attack by CD8+ CTLs and help to achieve pCR.

Although patients with TNBC showed the best response to PST, those with residual disease after PST have been reported to have the poorest survival ([@bib6]; [@bib26]; [@bib3]). Therefore, in this aggressive type of breast cancer it is important to select those patients who will respond to a given chemotherapeutic regimen. Previously, [@bib35] reported that high numbers of TILs were associated with higher pCR rates in TNBC. In this study, we showed that CD4+, CD8+, and FOXP3+ TILs were associated with pCR in TNBC, even though they were correlated with the CD44+/CD24− BCSC phenotype and vimentin expression within that subtype. However, our study has several limitations: the low number of TNBC cases, the use of a variety of different chemotherapeutic regimens, and its retrospective nature. Thus, further large studies will be needed to confirm the predictive value of TIL subsets, especially CD8+ CTLs, in chemotherapy of TNBCs.

Despite tumour immunosurveillance, tumour cells escape the innate and adaptive immune systems, and tumours develop. Thus, the idea of immunoediting, a concept used to describe the dynamic interaction of tumours with the immune system, has emerged ([@bib15]). It has been reported that immunoediting in a mouse model of breast cancer relapse gave rise to tumours that had undergone EMT and had characteristics of BCSCs ([@bib22]; [@bib40]). Moreover, immune cells are known to produce various EMT mediators, including TGF*β* and TNF*α* ([@bib38]). In this study, we showed for the first time that TILs were closely correlated with the BCSC phenotype and the expression of EMT markers in human breast cancer samples. Moreover, CD4+ or CD8+ TILs were correlated with CD44+/CD24− BCSCs and vimentin expression even in the triple-negative subtype, supporting the hypothesis that TILs promote EMT and the BCSC phenotype ([@bib38]). However, the most important conclusion from this study is that CD8+ TILs influence the response to chemotherapy even in tumours containing CD44+/CD24− BCSCs and in which vimentin is expressed.

In our study, none of the patients with HER2-positive breast cancer was treated by neoadjuvant trastuzumab. Several studies showed that the addition of trastuzumab to neoadjuvant chemotherapy significantly increased pCR rate in HER2-positive breast cancer ([@bib4]; [@bib17]; [@bib20]). However, despite its clinical benefits, the primary and/or acquired resistance to trastuzumab is frequent and thus requires new therapeutic approaches to improve its efficacy. Now, combination of active immunotherapy using various active vaccinal approaches and trastuzumab or lapatinib have been under clinical investigations in HER2-positive breast cancer ([@bib33]). It was reported that addition of stimulated *γδ* T lymphocytes increased the efficacy of trastuzumab against HER2+ mammary carcinoma xenografts in mice ([@bib5]). Thus, further studies will be needed to evaluate the predictive role of TILs in response to HER2-targeted therapy, including trastuzuamb.

We found that the expression of some EMT markers, including vimentin and osteonectin, was significantly associated with the likelihood of pCR in breast cancer. This finding seems to indicate that EMT is associated with chemo-sensitivity, which appears to contradict its role in chemo-resistance. However, the expression of EMT markers is a characteristic of TNBC, as shown in this study, and these markers were not associated with pCR in our analysis according to breast cancer subtype. Taken together, these findings suggest that the reason why tumours with EMT features tend to achieve pCR is related to their association with TNBC not to their EMT features *per se*.

In summary, our study demonstrates that the presence of TILs is strongly associated with pCR and that the presence of CD8+ CTLs in particular is an independent predictive factor for pCR in breast cancer patients treated by antracycline- or antracycline/taxane-based PST. Moreover, a high level of infiltration of CD8+ CTLs is correlated with pCR regardless of breast cancer subtype, BCSC phenotype, and EMT represented by vimentin expression. These findings suggest that CD8+ CTLs are the key component of TILs associated with chemo-response and might be used as a predictive marker to select patients who are more likely to respond to anthracycline- or antracycline/taxane-based PST.
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![**Intratumoural infiltration of CD4+, CD8+, and FOXP3+ T lymphocytes.** High levels of infiltration of CD4+, CD8+, and FOXP3+ T lymphocytes (**A**--**C**) are seen in some tumours while in others there is almost no infiltration (**D**--**F**).](bjc2013634f1){#fig1}

![**Expression of breast cancer stem cell and epithelial--mesenchymal transition markers according to intratumoural infiltration of CD8+ cytotoxic T lymphocytes.** (**A**) A representative example with infiltration of CD8+ CTLs into the tumour. CD44+/CD24− and ALDH1+ tumuor cells are present, as well as the expression of vimentin and osteonectin. (**B**) On the other hand, in this tumour with no infiltration of CD8+ CTLs, there is no expression of CD44+/CD24−, ALDH1, vimentin, or osteonectin.](bjc2013634f2){#fig2}

![**Box plots of the number of CD4+, CD8+, and FOXP3+ tumour-infiltrating lymphocytes and the ratio of CD8+/CD4+, CD4+/FOXP3+, and CD8+/FOXP3+ T cells in relation to pathological complete response following primary systemic therapy.** The group displaying a pathological complete response has higher numbers of (**A**) CD4+, (**B**) CD8+, and (**C**) FOXP3+ tumour-infiltrating lymphocytes and (**D**) higher ratio of CD8+/CD4+ T cells than the non-pCR group. There are no differences in the ratios of (**E**) CD4+/FOXP3+ and (**F**) CD8+/FOXP3+ T cells between the pCR and non-pCR groups. The box shows the 25th to 75th percentile, the horizontal line inside the box represents the median, the whiskers extend to the 10th and 90th percentiles, and the outlying black circles are individual data points outside the 10th and 90th percentiles.](bjc2013634f3){#fig3}

###### Clinicopathological characteristics of the patients

                                        **Non-pCR group**   **pCR group**     
  ------------------------------- ----- ------------------- ---------------- -------------
  **Age**                                                                    **0.107**
  Mean±s.d.                             48.63 (±10.926)     44.50 (±8.351)    
  **Clinical stage**                                                         **0.387**
  II                              78    66 (49.6)           12 (60.0)         
  III                             75    67 (50.4)           8 (40.0)          
  **Clinical T stage**                                                       **0.926**
  T1                              6     5 (3.8)             1 (5.0)           
  T2                              93    82 (61.7)           11 (55.0)         
  T3                              45    38 (28.6)           7 (35.0)          
  T4                              9     8 (6.0)             1 (5.0)           
  **Clinical N stage**                                                       **0.259**
  N0                              18    14 (10.5)           4 (20.0)          
  N1-N3                           135   119 (89.5)          16 (80.0)         
  **Histological subtype**                                                   **0.934**
  IDC                             142   123 (92.5)          19 (95.0)         
  ILC                             6     5 (3.8)             1 (5.0)           
  Metaplastic carcinoma           1     1 (0.8)             0 (0)             
  Micropapillary carcinoma        2     2 (1.5)             0 (0)             
  Mucinous carcinoma              2     2 (1.5)             0 (0)             
  **Histological grade**                                                     **\<0.001**
  Low (I and II)                  99    93 (69.9)           6 (30.0)          
  High (III)                      54    40 (30.1)           14 (70.0)         
  **Estrogen receptor**                                                      **\<0.001**
  Negative                        53    39 (29.3)           14 (70.0)         
  Positive                        100   94 (70.7)           6 (30.0)          
  **HER2 status**                                                            **0.082**
  Negative                        118   106 (79.7)          12 (60.0)         
  Positive                        35    27 (20.3)           8 (40.0)          
  **Molecular subtype**                                                      **\<0.001**
  Luminal A                       45    45 (33.8)           0 (0)             
  Luminal B                       36    35 (26.3)           1 (5.0)           
  Luminal B/HER2+                 21    16 (12.0)           5 (25.0)          
  HER2+                           13    10 (7.5)            3 (15.0)          
  Triple-negative                 38    27 (20.3)           11 (55.0)         
  **Ki-67 proliferation index**                                              **\<0.001**
  ⩽20%                            76    74 (55.6)           2 (10.0)          
  \>20%                           77    59 (44.4)           18 (90.0)         
  **Chemotherapy regimen**                                                   **0.117**
  AC                              66    60 (45.1)           6 (30.0)          
  AD                              47    42 (23.3)           5 (25.0)          
  ACT                             40    31 (31.6)           9 (45.0)          

Abbreviations: AC=doxorubicin plus cyclophosphamide; ACT=AC followed by docetaxel; AD=doxorubicin plus docetaxel; IDC=invasive ductal carcinoma; ILC=invasive lobular carcinoma; pCR=pathological complete response.

*P* values were calculated by independent sample *t*-tests and Chi-square or Fisher\'s exact tests.

###### Association of subsets of tumour-infiltrating lymphocytes with clinicopathological characteristics of tumour

                           **CD4+ TILs**               **CD8+ TILs**               **FOXP3+ TILs**                                         
  ------------------------ --------------- ----------- --------------- ----------- ----------------- ------------- ----------- ----------- -------------
  **Clinical stage**                                   **0.029**                                     **0.375**                             **0.228**
  II                       33 (42.3)       45 (60.0)                   36 (47.4)   42 (54.5)                       34 (45.9)   44 (55.7)    
  III                      45 (57.7)       30 (40.0)                   40 (52.6)   35 (45.5)                       40 (54.1)   35 (44.3)    
  **Histological grade**                               **\<0.001**                                   **0.003**                             **0.002**
  Low (I and II)           62 (79.5)       37 (49.3)                   58 (76.3)   41 (53.2)                       57 (77.0)   42 (53.2)    
  High (III)               16 (20.5)       38 (50.7)                   18 (23.7)   36 (46.8)                       17 (23.0)   37 (46.8)    
  **Estrogen receptor**                                **0.006**                                     **\<0.001**                           **0.001**
  Negative                 19 (24.4)       34 (45.3)                   15 (19.7)   38 (49.4)                       16 (21.6)   37 (46.8)    
  Positive                 59 (75.6)       41 (54.7)                   61 (80.3)   39 (50.6)                       58 (78.4)   42 (53.2)    
  **HER2 status**                                      **0.656**                                     **0.358**                             **0.458**
  Negative                 59 (75.6)       59 (78.7)                   61 (80.3)   57 (74.0)                       59 (79.7)   59 (74.7)    
  Positive                 19 (24.4)       16 (21.3)                   15 (19.7)   20 (26.0)                       15 (20.3)   20 (25.3)    
  **Subtype**                                          **\<0.001**                                   **\<0.001**                           **0.002**
  Non-TN                   68 (87.2)       47 (62.7)                   67 (88.2)   48 (62.3)                       64 (86.5)   51 (64.6)    
  TN                       10 (12.8)       28 (37.3)                   9 (11.8)    29 (37.7)                       10 (13.5)   28 (35.4)    
  **Ki-67 index**                                      **0.003**                                     **0.043**                             **\<0.001**
  Low (⩽20%)               48 (61.5)       28 (37.3)                   44 (57.9)   32 (41.6)                       48 (64.9)   28 (35.4)    
  High (\>20%)             30 (38.5)       47 (62.7)                   32 (42.1)   45 (58.4)                       26 (35.1)   51 (64.6)    

Abbreviations: TIL=tumour-infiltrating lymphocyte; TN=triple-negative.

###### Correlation of subsets of tumour-infiltrating lymphocytes with breast cancer stem cells and epithelial--mesenchymal transition markers

                     **Total**              **TNBC**                                                            
  ------------------ ----------------- ------------------ ----------------- ----------------- ----------------- -----------------
  **TILs**                                                                                                      
  CD4+ TILs          ---                0.608 (\<0.001)   0.504 (\<0.001)   ---                0.651 (\<0.001)  0.593 (\<0.001)
  CD8+ TILs          0.608 (\<0.001)          ---         0.634 (\<0.001)   0.651 (\<0.001)          ---        0.792 (\<0.001)
  FOXP3+ TILs        0.504 (\<0.001)    0.634 (\<0.001)   ---               0.593 (\<0.001)    0.792 (\<0.001)  ---
  **BCSC markers**                                                                                              
  CD44+/CD24−        0.194 (0.016)       0.296 (\<0.001)  0.134 (0.098)     0.394 (0.014)       0.423 (0.008)   0.127 (0.448)
  ALDH1              0.193 (0.017)       0.225 (0.005)    0.174 (0.032)     0.192 (0.247)       0.165 (0.323)   0.052 (0.757)
  **EMT markers**                                                                                               
  Vimentin           0.358 (\<0.001)     0.220 (0.007)    0.236 (\<0.001)   0.424 (0.008)       0.016 (0.924)   0.131 (0.443)
  SMA                0.210 (0.009)       0.119 (0.142)    0.069 (0.395)     0.053 (0.752)      −0.120 (0.472)   −0.073 (0.663)
  Osteonectin        0.253 (0.002)       0.169 (0.038)    0.155 (0.057)     0.129 (0.441)      −0.197 (0.237)   −0.116 (0.489)
  N-cadherin         0.005 (0.949)       −0.002 (0.983)   −0.009 (0.916)    0.175 (0.293)      −0.066 (0.692)   −0.268 (0.103)
  E-cadherin loss    −0.114 (0.159)      −0.019 (0.820)   −0.008 (0.926)    −0.031 (0.851)     −0.091 (0.585)   0.088 (0.599)

Abbreviations: ALDH1=aldehyde dehydrogenase 1; EMT=epithelial--mesenchymal transition; SMA=smooth muscle actin; TNBC=triple-negative breast cancer; TIL=tumour-infiltrating lymphocyte.

*P*-values and *ρ*correlation coefficient were calculated by Spearman\'s rank correlation test.

###### Predictive factors for pathological complete response in univariate and multivariate logistic regression analyses

                                                               **Univariate analysis**    **Multivariate analysis**                                    
  ---------------------------------------- ------------------- ------------------------- --------------------------- --------- ------- --------------- -------
  Histological grade                            Low/high       5.425                            1.945--15.130        0.001     1.637    0.425--6.306   0.474
  Estrogen receptor                         Positive/negative  5.624                            2.015--15.700        0.001     1.468    0.244--8.828   0.675
  Subtype                                       Non-TN/TN      4.798                            1.806--12.747        0.002     0.683    0.120--3.888   0.668
  Ki-67 index                                  ⩽20%/\>20%      11.288                           2.518--50.610        0.002     9.786    2.121--45.149  0.003
  CD4+ TILs[a](#t4-fn3){ref-type="fn"}          Low/high       7.328                            2.019--26.206        0.002     2.377    0.483--11.688  0.287
  CD8+ TILs[a](#t4-fn3){ref-type="fn"}          Low/high       11.288                           2.518--50.610        0.002     9.786    2.121--45.149  0.003
  FOXP3+ TILs[a](#t4-fn3){ref-type="fn"}        Low/high       4.444                            1.411--13.999        0.011     0.292    0.039--2.212   0.234
  Vimentin                                  Negative/positive  6.360                            2.351--17.204        \<0.001   ---           ---       ---
  Osteonectin                               Negative/positive  3.682                            1.374--9.867         0.010     1.561    0.444--5.483   0.488

Abbreviations: CI=confidence interval; OR=odds ratio; TIL=tumour-infiltrating lymphocyte; TN=triple-negative.

*P*-values were calculated by univariate and multivariate binary logistic regression analysis. Backward selection strategies were used for multivariate logistic regression analysis. Vimentin is not included in multivariate analysis, because it is highly correlated with the triple-negative subtype (*ρ*=0.734, *P*\<0.001).

Samples were classified as low and high according to the median values of CD4+, CD8+, and FOXP3+ TILs.
